Grant: Operating Grant: Industry-partnered Collaborative Research
University of British Columbia
$419,232.00
A Defined Abeta Oligomer Epitope: Theranostic Applications
FY 2014-15
Summary
Identification of methods for early diagnosis and treatment of Alzheimer's disease is a top priority for medical science. Small aggregates of the protein amyloid-beta called oligomers have been identified as being the primary toxic agent in Alzheimer's disease. We have identified an A-beta oligomer specific targeting site (termed cSNK). The target is comprised of three amino acids in a distinct 3-dimensional arrangement. We have confirmed that antibodies binding to this target site specifically recognize oligomers in brain extract, plasma, and spinal fluid of Alzheimer's disease patients. In 2012 the cSNK epitope and antibodies were exclusively licensed from UBC to Cangene Corp/Emergent BioSolutions (Winnipeg MB). Together with the company we detected circulating cSNK "natural antibodies" in young healthy donors, the titers of which declined in aging. Jointly with Emergent BioSolutions, we will exploit our unique tools to develop effective diagnostic and therapeutic applications of the cSNK epitope.
Department
Program
Operating Grant: Industry-partnered Collaborative Research
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
324767
Name
Cashman Neil R
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Partnername
Emergent BioSolutions (Winnipeg, Manitoba); Emergent BioSolutions (Winnipeg, Manitoba)
Instname2
Aging
Theme2
Biomedical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
A Defined Abeta Oligomer Epitope: Theranostic Applications
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$419,232
Cihrequipment2
$0
Programname2
Operating Grant: Industry-partnered Collaborative Research
Keyworddelim
Abeta Oligomers; Active Immunization; Alzheimer Disease; Biomarkers; Commercialization; Diagnosis; Knowledge Translation; Oligomer-Specific Antibodies; Passive Immunization; Therapeutic
Abstract
Identification of methods for early diagnosis and treatment of Alzheimer's disease is a top priority for medical science. Small aggregates of the protein amyloid-beta called oligomers have been identified as being the primary toxic agent in Alzheimer's disease. We have identified an A-beta oligomer specific targeting site (termed cSNK). The target is comprised of three amino acids in a distinct 3-dimensional arrangement. We have confirmed that antibodies binding to this target site specifically recognize oligomers in brain extract, plasma, and spinal fluid of Alzheimer's disease patients. In 2012 the cSNK epitope and antibodies were exclusively licensed from UBC to Cangene Corp/Emergent BioSolutions (Winnipeg MB). Together with the company we detected circulating cSNK "natural antibodies" in young healthy donors, the titers of which declined in aging. Jointly with Emergent BioSolutions, we will exploit our unique tools to develop effective diagnostic and therapeutic applications of the cSNK epitope.
Competitiondate
201503
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cashman, Neil R
Approvedterm
3 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $419,232~ $0~
